FDA Could Authorize Novavax COVID Vaccine by February, But Is It ‘Safe and Effective?’

The U.S. Food and Drug Administration could authorize the Novavax vaccine by February. Unlike the Pfizer and Moderna mRNA vaccines, Novavax relies on more conventional vaccine technology shown in clinical trials to have fewer side effects, but safety of spike protein still in question.

Novavax said its vaccine showed “cross-reactive immune response” against Omicron and other coronavirus variants, though the company noted the efficacy against the Omicron variant was four times lower than for the original Wuhan strain.

The vaccine is tested using fetal cell lines.

Recent Posts

See All

The Centers for Disease Control and Prevention (CDC) revised its COVID-19 guidance on Aug. 11, stating that the United States should move away from quarantines and social distancing and focus on treat